Enasidenib (AG-221) Maintenance Post Allogeneic HCT in Patients With IDH2 Mutation

This trial is studying a drug called enasidenib (AG-221) as a maintenance therapy for people with a type of blood cancer (AML) who carry a specific genetic mutation (IDH2) and have recently received a bone marrow transplant. **You may be eligible if...** - You have been diagnosed with acute myeloid leukemia (AML) with an IDH2 gene mutation - You have recently had an allogeneic stem cell (bone marrow) transplant - Your overall performance is reasonably good (ECOG ≤ 2 or Karnofsky ≥ 70) - You are in remission (no active leukemia signs) after your transplant - You are 18 years or older and able to give informed consent **You may NOT be eligible if...** - You have not had a bone marrow/stem cell transplant - You do not have the IDH2 mutation in your leukemia cells - Your leukemia has relapsed or is active - You have severe organ problems that would make treatment unsafe Talk to your doctor to see if this trial is right for you.